Ligand Pharmaceuticals (LGND) EPS (Basic) Growth (1y) (2011 - 2026)
Ligand Pharmaceuticals (LGND) EPS (Basic) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 29.25% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17,151.81% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 61.34% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -7.74% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 88.81% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | 69.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.66% |
| Dec 31, 2025 | 236.25% |
| Mar 31, 2023 | 33.16% |
| Dec 31, 2022 | -30.88% |
| Sep 30, 2022 | -38.04% |
| Jun 30, 2022 | -133.11% |
| Mar 31, 2022 | 48.51% |
| Dec 31, 2021 | -112.30% |
| Sep 30, 2021 | 4.87% |
| Jun 30, 2021 | -124.95% |
| Mar 31, 2021 | 80.58% |
| Dec 31, 2020 | 380.31% |
| Sep 30, 2020 | 48.72% |
| Jun 30, 2020 | 286.59% |
| Mar 31, 2020 | -104.48% |
| Dec 31, 2019 | 80.69% |
| Sep 30, 2019 | -125.51% |
| Jun 30, 2019 | -121.38% |
| Mar 31, 2019 | 1,426.47% |
| Jun 30, 2013 | 45.32% |